Health Awareness

Jupiter, Florida 33458

1 studies enrolling now · 13 studies all time

What they study most

Acute Gout, Acute Gouty Arthritis, COVID-19, Diabetic Peripheral Neuropathy, Gout, Hot Flashes, Infectious Disease, Influenza, Human, Knee Osteoarthritis, Metabolic Dysfunction-Associated Steatotic Liver Disease, Pneumococcal Vaccines, Respiratory Syncytial Virus (RSV)

Studies at this site

• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) — Recruiting now
• A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age — Running, not enrolling
• A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV — Running, not enrolling
• Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults — Completed
• A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older — Completed
• Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines — Completed
• A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause — Completed
• A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause — Completed
• Study to Evaluate the Iovera° Device for Temporary Relief From Knee Pain — Completed
• A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis — Completed
• A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study) — Completed
• Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study. — Completed
• IMX-150 Cream for Diabetic Neuropathy — Completed